Yukiko Kunitomo1,2,3, Brett Bade1,2,3, Craig G Gunderson1,2,3, Kathleen M Akgün1,2,3, Alexandria Brackett4, Lynn Tanoue3, Lori A Bastian5,6,7. 1. Pain Research, Informatics, Multi-morbidities, and Education (PRIME) Center, VA Connecticut Healthcare System, West Haven, CT, USA. 2. Department of Internal Medicine, VA Connecticut Healthcare System, West Haven, CT, USA. 3. Yale University School of Medicine, New Haven, CT, USA. 4. Harvey Cushing/John Hay Whitney Medical Library, Yale University School of Medicine, New Haven, CT, USA. 5. Pain Research, Informatics, Multi-morbidities, and Education (PRIME) Center, VA Connecticut Healthcare System, West Haven, CT, USA. Lori.Bastian@va.gov. 6. Department of Internal Medicine, VA Connecticut Healthcare System, West Haven, CT, USA. Lori.Bastian@va.gov. 7. Yale University School of Medicine, New Haven, CT, USA. Lori.Bastian@va.gov.
Abstract
BACKGROUND: Annual lung cancer screening (LCS) with low-dose chest computed tomography for high-risk individuals reduces lung cancer mortality, with greater reduction observed in Black participants in clinical trials. While racial disparities in lung cancer mortality exist, less is known about disparities in LCS participation. We conducted a systematic review to explore LCS participation in Black compared with White patients in the USA. METHODS: A systematic review was conducted through a search of published studies in MEDLINE, PubMed, EMBASE, Web of Science, and Cumulative Index to Nursing and Allied-Health Literature Database, from database inception through October 2020. We included studies that examined rates of LCS participation and compared rates by race. Studies were pooled using random-effects meta-analysis. RESULTS: We screened 18,300 titles/abstracts; 229 studies were selected for full-text review, of which nine studies met inclusion criteria. Studies were categorized into 2 groups: studies that reported the screening rate among an LCS-eligible patient population, and studies that reported the screening rate among a patient population referred for LCS. Median LCS participation rates were 14.4% (range 1.7 to 62.6%) for eligible patient studies and 68.5% (range 62.6 to 88.8%) for referred patient studies. The meta-analyses showed screening rates were lower in the Black compared to White population among the LCS-eligible patient studies ([OR]=0.43, [95% CI: 0.25, 0.74]). However, screening rates were the same between Black and White patients in the referred patient studies (OR=0.94, [95% CI: 0.74, 1.19]). DISCUSSION: Black LCS-eligible patients are being screened at a lower rate than White patients but have similar rates of participation once referred. Differences in referrals by providers may contribute to the racial disparity in LCS participation. More studies are needed to identify barriers to LCS referral and develop interventions to increase provider awareness of the importance of LCS in Black patients. Trial Registry PROSPERO; No.: CRD42020214213; URL: http://www.crd.york.ac.uk/PROSPERO.
BACKGROUND: Annual lung cancer screening (LCS) with low-dose chest computed tomography for high-risk individuals reduces lung cancer mortality, with greater reduction observed in Black participants in clinical trials. While racial disparities in lung cancer mortality exist, less is known about disparities in LCS participation. We conducted a systematic review to explore LCS participation in Black compared with White patients in the USA. METHODS: A systematic review was conducted through a search of published studies in MEDLINE, PubMed, EMBASE, Web of Science, and Cumulative Index to Nursing and Allied-Health Literature Database, from database inception through October 2020. We included studies that examined rates of LCS participation and compared rates by race. Studies were pooled using random-effects meta-analysis. RESULTS: We screened 18,300 titles/abstracts; 229 studies were selected for full-text review, of which nine studies met inclusion criteria. Studies were categorized into 2 groups: studies that reported the screening rate among an LCS-eligible patient population, and studies that reported the screening rate among a patient population referred for LCS. Median LCS participation rates were 14.4% (range 1.7 to 62.6%) for eligible patient studies and 68.5% (range 62.6 to 88.8%) for referred patient studies. The meta-analyses showed screening rates were lower in the Black compared to White population among the LCS-eligible patient studies ([OR]=0.43, [95% CI: 0.25, 0.74]). However, screening rates were the same between Black and White patients in the referred patient studies (OR=0.94, [95% CI: 0.74, 1.19]). DISCUSSION: Black LCS-eligible patients are being screened at a lower rate than White patients but have similar rates of participation once referred. Differences in referrals by providers may contribute to the racial disparity in LCS participation. More studies are needed to identify barriers to LCS referral and develop interventions to increase provider awareness of the importance of LCS in Black patients. Trial Registry PROSPERO; No.: CRD42020214213; URL: http://www.crd.york.ac.uk/PROSPERO.
Authors: Hannah E Modin; Joelle T Fathi; Christopher R Gilbert; Candice L Wilshire; Andrew K Wilson; Ralph W Aye; Alexander S Farivar; Brian E Louie; Eric Vallières; Jed A Gorden Journal: Ann Am Thorac Soc Date: 2017-08
Authors: Gary X Wang; Travis P Baggett; Pari V Pandharipande; Elyse R Park; Sanja Percac-Lima; Jo-Anne O Shepard; Florian J Fintelmann; Efren J Flores Journal: Radiology Date: 2019-01-08 Impact factor: 11.105
Authors: Catherine Duda; Irene Mahon; Mei Hsiu Chen; Bradley Snyder; Richard Barr; Caroline Chiles; Robert Falk; Elliot K Fishman; David Gemmel; Jonathan G Goldin; Kathleen Brown; Reginald F Munden; Kay Vydareny; Denise R Aberle Journal: Clin Trials Date: 2011-01-17 Impact factor: 2.486
Authors: Jennifer Richmond; Olive M Mbah; Sofia Z Dard; Lauren C Jordan; Katherine S Cools; Cleo A Samuel; Jalaal M Khan; Matthew A Manning Journal: J Natl Med Assoc Date: 2020-02-15 Impact factor: 1.798
Authors: Lior Rennert; Lu Zhang; Brandon Lumsden; Katon Harwood; Lauren Tyler; Morgan Ashby; Jeffrey W Hanna; Ronald W Gimbel Journal: Cancer Treat Res Commun Date: 2020-07-17
Authors: Nancy Krieger; Emily Wright; Jarvis T Chen; Pamela D Waterman; Eric R Huntley; Mariana Arcaya Journal: Am J Epidemiol Date: 2020-03-27 Impact factor: 4.897
Authors: Valentina A Zavala; Paige M Bracci; John M Carethers; Luis Carvajal-Carmona; Nicole B Coggins; Marcia R Cruz-Correa; Melissa Davis; Adam J de Smith; Julie Dutil; Jane C Figueiredo; Rena Fox; Kristi D Graves; Scarlett Lin Gomez; Andrea Llera; Susan L Neuhausen; Lisa Newman; Tung Nguyen; Julie R Palmer; Nynikka R Palmer; Eliseo J Pérez-Stable; Sorbarikor Piawah; Erik J Rodriquez; María Carolina Sanabria-Salas; Stephanie L Schmit; Silvia J Serrano-Gomez; Mariana C Stern; Jeffrey Weitzel; Jun J Yang; Jovanny Zabaleta; Elad Ziv; Laura Fejerman Journal: Br J Cancer Date: 2020-09-09 Impact factor: 9.075